Ricky Goldwasser
Stock Analyst at Morgan Stanley
(2.94)
# 1,281
Out of 4,829 analysts
231
Total ratings
71.43%
Success rate
15.67%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $61.04 | -1.70% | 10 | Apr 24, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $664 → $563 | $378.75 | +48.65% | 16 | Apr 22, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $184 | $143.08 | +28.60% | 20 | Feb 5, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $260 → $270 | $250.94 | +7.60% | 15 | Dec 17, 2024 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $5.85 | +70.94% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.35 | +26.44% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $16.82 | -55.41% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $14.92 | -19.57% | 8 | Aug 30, 2023 | |
| CNC Centene | Downgrades: Equal-Weight | $94 → $73 | $62.87 | +16.11% | 10 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $175.90 | -17.57% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $327.69 | +11.39% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $687.52 | -38.91% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $7.21 | +1,564.36% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $252.86 | +145.19% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $416.69 | +19.99% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $64.81 | +91.33% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $315.74 | +0.72% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $148.62 | -52.90% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $11.40 | +242.11% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $156.13 | +24.90% | 6 | Oct 21, 2020 |
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $61.04
Upside: -1.70%
UnitedHealth Group
Apr 22, 2025
Maintains: Overweight
Price Target: $664 → $563
Current: $378.75
Upside: +48.65%
Charles River Laboratories International
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $220 → $184
Current: $143.08
Upside: +28.60%
Labcorp Holdings
Dec 17, 2024
Maintains: Overweight
Price Target: $260 → $270
Current: $250.94
Upside: +7.60%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $5.85
Upside: +70.94%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.35
Upside: +26.44%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $16.82
Upside: -55.41%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $14.92
Upside: -19.57%
Centene
Aug 30, 2023
Downgrades: Equal-Weight
Price Target: $94 → $73
Current: $62.87
Upside: +16.11%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $175.90
Upside: -17.57%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $327.69
Upside: +11.39%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $687.52
Upside: -38.91%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $7.21
Upside: +1,564.36%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $252.86
Upside: +145.19%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $416.69
Upside: +19.99%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $64.81
Upside: +91.33%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $315.74
Upside: +0.72%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $148.62
Upside: -52.90%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $11.40
Upside: +242.11%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $156.13
Upside: +24.90%